Alpha galactosidase: Completed Phase I/II enrollment

Protalix completed enrollment of 18 treatment-naïve patients in an open-label, dose-escalation, international Phase I/II trial evaluating 0.2, 1 and 2 mg/kg IV PRX-102 every 2 weeks for 12 weeks. All ...